Author:
Ayoub Walaa A.,Kumar Ashok A.,Naguib Hossam S.,Taylor Harris C.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference17 articles.
1. Glucagon-like peptide 1-based therapies for type 2 diabetes: a focus on exenatide;Dungan;Clin Diabetes,2005
2. Pharmoacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus;Kolterman;Am J Health Syst Pharm,2005
3. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea;Kendall;Diabetes Care.,2005
4. US Food and Drug Administration. FDA alert: Information for healthcare professionals: exenatide (marketed as Byetta). Available at: http://www.fda.gov/Drugs/DrugSafety/ostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm
5. Exenatide and rare adverse events;Cure;N Engl J Med.,2008
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献